BTAI

1.93

2.03% -0.04

Handel nachbörslich: 1.90 -0.03 -1.55%

Bioxcel Therapeutics Inc (BTAI)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt BTAI? Forum Prognose

Schlusskurs vom Vortag:

$1.97

Offen:

$1.99

24-Stunden-Volumen:

215.14K

Relative Volume:

0.73

Marktkapitalisierung:

$12.05M

Einnahmen:

$1.38M

Nettoeinkommen (Verlust:

$-179.05M

KGV:

-0.3143

EPS:

-6.14

Netto-Cashflow:

$-155.03M

1W Leistung:

-5.85%

1M Leistung:

+46.21%

6M Leistung:

+392.35%

1J Leistung:

+72.32%

1-Tages-Spanne:

$1.88

$2.00

1-Wochen-Bereich:

$1.69

$2.08

52-Wochen-Spanne:

$0.16

$6.83

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Firmenname

Bioxcel Therapeutics Inc

Sektor

Healthcare (1166)

Branche

Biotechnology (655)

Telefon

203-643-8060

Adresse

555 LONG WHARF DRIVE, NEW HAVEN, CT

Mitarbeiter

Twitter

@bioxcel_tx

Nächster Verdiensttermin

2024-11-12

Neueste SEC-Einreichungen

BTAI's Discussions on Twitter

Vergleichen Sie BTAI mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BTAI Bioxcel Therapeutics Inc	1.93	12.05M	1.38M	-179.05M	-155.03M	-6.14
VRTX Vertex Pharmaceuticals Inc	457.03	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	547.74	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	329.77	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	545.11	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	244.32	28.51B	3.81B	-644.79M	-669.77M	-6.24

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-02-21	Herabstufung	UBS	Buy → Neutral
2023-08-15	Herabstufung	Mizuho	Buy → Neutral
2023-07-17	Herabstufung	Guggenheim	Buy → Neutral
2023-03-10	Herabstufung	Jefferies	Buy → Hold
2022-12-01	Hochstufung	Goldman	Sell → Neutral
2022-07-07	Eingeleitet	Mizuho	Buy
2022-04-06	Bestätigt	BofA Securities	Buy
2021-11-15	Herabstufung	Goldman	Neutral → Sell
2021-04-09	Eingeleitet	Berenberg	Buy
2021-02-01	Eingeleitet	UBS	Buy
2020-10-30	Eingeleitet	Goldman	Buy
2020-09-02	Eingeleitet	Jefferies	Buy
2020-08-17	Bestätigt	H.C. Wainwright	Buy
2020-07-08	Bestätigt	H.C. Wainwright	Buy
2020-06-04	Eingeleitet	Guggenheim	Buy
2020-04-01	Eingeleitet	BofA/Merrill	Buy
2020-02-26	Bestätigt	H.C. Wainwright	Buy
2020-01-08	Bestätigt	H.C. Wainwright	Buy
2019-11-12	Eingeleitet	SunTrust	Buy

Alle ansehen

Bioxcel Therapeutics Inc Aktie (BTAI) Neueste Nachrichten

Jun 16, 2025

BioXcel Therapeutics Requests to Dismiss Class Action Filed by Investors - TradingView

Jun 16, 2025

May 30, 2025

Real-World Deployments Signal AI Healthcare Is Ready for Scale - FinancialContent

May 30, 2025

BioXcel Therapeutics stock hits 52-week low at $1.24 By Investing.com - Investing.com South Africa

May 30, 2025

May 29, 2025

BioXcel Therapeutics stock hits 52-week low at $1.24 - Investing.com Australia

May 29, 2025

SHAREHOLDER ALERT: Potential Recovery for BioXcel Therapeutics, Inc. (BTAI) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

May 29, 2025

May 28, 2025

BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement - Revista ADVFN

May 28, 2025

BioXcel Therapeutics Receives Positive Recommendation from Data - GuruFocus

May 28, 2025

May 27, 2025

BTAIBioXcel Therapeutics Provides Clinical and Business Update - mx.advfn.com

May 27, 2025

BioXcel’s Phase 3 trial of BXCL501 continues as advised by DSMB - Investing.com India

May 27, 2025

BioXcel Therapeutics (BTAI) Granted Extension to Retain Nasdaq L - GuruFocus

May 27, 2025

BioXcel Therapeutics granted Nasdaq extension - Investing.com Australia

May 27, 2025

BioXcel granted an extension for compliance by Nasdaq - Hartford Business Journal

May 27, 2025

BioXcel Therapeutics granted Nasdaq extension By Investing.com - Investing.com South Africa

May 27, 2025

BTAI's Phase 3 Trial for BXCL501 Advances Unhindered by Safety Concerns | BTAI Stock News - GuruFocus

May 27, 2025

BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated wit - GuruFocus

May 27, 2025

Bioxcel Therapeutics Granted Extension To Regain Compliance With Nasdaq Continued Listing Requirement - marketscreener.com

May 27, 2025

BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewswire

May 27, 2025

BioXcel Therapeutics (BTAI) Granted Extension to Retain Nasdaq Listing - GuruFocus

May 27, 2025

BioXcel's Breakthrough At-Home Agitation Drug Clears Critical Safety Review, First FDA Approval Possible - Stock Titan

May 27, 2025

BioXcel Therapeutics (BTAI) Secures Continued Nasdaq Listing | B - GuruFocus

May 27, 2025

BioXcel Granted Nasdaq Compliance Extension Until September - TipRanks

May 27, 2025

BioXcel Therapeutics (BTAI) Secures Continued Nasdaq Listing | BTAI Stock News - GuruFocus

May 27, 2025

BioXcel Gets Critical Nasdaq Reprieve: 4-Month Extension as Phase 3 Trial Results Near - Stock Titan

May 27, 2025

May 26, 2025

BioXcel Therapeutics stock hits 52-week low at $0.3 - MSN

May 26, 2025

May 24, 2025

Can a $10,000 Investment in SoundHound AI Turn Into $1 Million by 2035? - The Globe and Mail

May 24, 2025

May 18, 2025

BIOXCEL DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioXcel To Contact Him Directly To Discuss Their Options - The Globe and Mail

May 18, 2025

May 14, 2025